Please note: this site relies heavily on the use of javascript. Without a javascript-enabled browser, this site will not function correctly. Please enable javascript and reload the page, or switch to a different browser.
0  structures 109  species 0  interactions 154  sequences 3  architectures

Family: Fanconi_A (PF03511)

Summary: Fanconi anaemia group A protein

Pfam includes annotations and additional family information from a range of different sources. These sources can be accessed via the tabs below.

This is the Wikipedia entry entitled "FANCA". More...

FANCA Edit Wikipedia article

AliasesFANCA, FA, FA-H, FA1, FAA, FACA, FAH, FANCH, Fanconi anemia complementation group A, FA complementation group A
External IDsOMIM: 607139 MGI: 1341823 HomoloGene: 108 GeneCards: FANCA
Gene location (Human)
Chromosome 16 (human)
Chr.Chromosome 16 (human)[1]
Chromosome 16 (human)
Genomic location for FANCA
Genomic location for FANCA
Band16q24.3Start89,737,549 bp[1]
End89,816,657 bp[1]
RNA expression pattern
PBB GE FANCA 203805 s at fs.png

PBB GE FANCA 203806 s at fs.png
More reference expression data
RefSeq (mRNA)



RefSeq (protein)



Location (UCSC)Chr 16: 89.74 – 89.82 MbChr 8: 123.27 – 123.32 Mb
PubMed search[3][4]
View/Edit HumanView/Edit Mouse

Fanconi anaemia, complementation group A, also known as FAA, FACA and FANCA, is a protein which in humans is encoded by the FANCA gene.[5] It belongs to the Fanconi anaemia complementation group (FANC) family of genes of which 12 complementation groups are currently recognized and is hypothesised to operate as a post-replication repair or a cell cycle checkpoint. FANCA proteins are involved in inter-strand DNA cross-link repair and in the maintenance of normal chromosome stability that regulates the differentiation of haematopoietic stem cells into mature blood cells.[6]

Mutations involving the FANCA gene are associated with many somatic and congenital defects, primarily involving phenotypic variations of Fanconi anaemia, aplastic anaemia, and forms of cancer such as squamous cell carcinoma and acute myeloid leukaemia.[7]


The Fanconi anaemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, and FANCL. The previously defined group FANCH is the same as FANCA. The members of the Fanconi anaemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. The FANCA gene encodes the protein for complementation group A. Alternative splicing results in multiple transcript variants encoding different isoforms.[5]

Fanconi anaemia group A protein

Gene and protein

In humans, the gene FANCA is 79 kilobases (kb) in length, and is located on chromosome 16 (16q24.3). The FANCA protein is composed of 1455 amino acids.[8] Within cells, the major purpose of FANCA belongs to its putative involvement in a multisubunit FA complex composed of FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL/PHF9 and FANCM. In complex with FANCF, FANCG and FANCL, FANCA interacts with HES1. This interaction has been proposed as essential for the stability and nuclear localization of FA core complex proteins. The complex with FANCC and FANCG may also include EIF2AK2 and HSP70.[9] In cells, FANCA involvement in this ‘FA core complex’ is required for the activation of the FANCD2 protein to a monoubiquitinated isoform (FANCD2-Ub) in response to DNA damage, catalysing activation of the FA/BRCA DNA damage-response pathway,[10] leading to repair.[11]

FANCA binds to both single-stranded (ssDNA) and double-stranded (dsDNA) DNAs; however, when tested in an electrophoretic mobility shift assay, its affinity for ssDNA is significantly higher than for dsDNA. FANCA also binds to RNA with a higher affinity than its DNA counterpart.[12] FANCA requires a certain number of nucleotides for optimal binding, with the minimum for FANCA recognition being approximately 30 for both DNA and RNA. Yuan et al. (2012) found through affinity testing FANCA with a variety of DNA structures that a 5'-flap or 5'-tail on DNA facilitates its interaction with FANCA, while the complementing C-terminal fragment of Q772X, C772-1455, retains the differentiated nucleic acid-binding activity (i.e. preferencing RNA before ssDNA and dsDNA), indicating that the nucleic acid-binding domain of FANCA is located primarily at the C terminus, a location where many disease-causing mutations are found.[12]

FANCA is ubiquitously expressed at low levels in all cells[13] with subcellular localisation in primarily nucleus but also cytoplasm[14] corresponding with its putative caretaker role in DNA damage-response pathways, and FA complex formation. The distribution of proteins in different tissues is not well understood currently. Immunochemical study of mouse tissue indicates that FANCA is present at a higher level in lymphoid tissues, the testis and the ovary,[13] and though the significance of this is unclear, it suggests that the presence of FA proteins might be related to cellular proliferation. For example, in human immortalized lymphoblasts and leukaemia cells, FA proteins are readily detectable by immunoprecipitation.[15]

Clinical significance

Mutations in this gene are the most common cause of Fanconi's anaemia.[5][6][7] Fanconi anaemia is an inherited autosomal recessive disorder, the main features of which are aplastic anaemia in childhood, multiple congenital abnormalities, susceptibility to leukemia and other cancers, and cellular hypersensitivity to interstrand DNA cross-linking agents.[7] Generally cells from Fanconi anaemia patients show a markedly higher frequency of spontaneous chromosomal breakage and hypersensitivity to the clastogenic effect of DNA cross-linking agents such as diepoxybutane (DEB) and mitomycin-C (MMC) when compared to normal cells. The primary diagnostic test for Fanconi anaemia is based on the increased chromosomal breakage seen in afflicted cells after exposure to these agents – the DEB/MMC stress test. Other features of the Fanconi anaemia cell phenotype also include abnormal cell cycle kinetics (prolonged G2 phase), hypersensitivity to oxygen, increased apoptosis and accelerated telomere shortening.[6][16]

FANCA mutations are by far the most common cause of Fanconi anaemia, accounting for between 60-70% of all cases. FANCA was cloned in 1996[17] and it is one of the largest FA genes. Hundreds of different mutations have been recorded[18][19] with 30% point mutations, 30% 1-5 base pair microdeletions or microinsertions, and 40% large deletions, removing up to 31 exons from the gene.[20] These large deletions have a high correlation with specific breakpoints and arise as a result of Alu mediated recombination. A highly relevant observation is that different mutations produce Fanconi anaemia phenotypes of varying severity.

Patients homozygous for null-mutations in this gene have an earlier onset of anaemia than those with mutations that produce an altered or incorrect protein.[21] However, as most patients are compound heterozygotes, diagnostic screening for mutations is difficult. Certain founder mutations can also occur in some populations, such as the deletion exon 12-31 mutation, which accounts for 60% of mutations in Afrikaners.[22]

Involvement in FA/BRCA pathway

In cells from Fanconi anaemia patients, FA core complex induction of FANCD2 ubiquitination is not observed, assumably a result from impaired complex formation due to the lack of a working FANCA protein.[23][24] Ultimately, regardless of specific mutation, it is disruption of this FA/BRCA pathway that results in the adverse cellular and clinical phenotypes common to all FANCA-impaired Fanconi anaemia sufferers.[6] Interactions between BRCA1 and many FANC proteins have been investigated. Amongst known FANC proteins, most evidence points for a direct interaction primarily between FANCA protein and BRCA1. Evidence from yeast two-hybrid analysis,[25] coimmunoprecipitation from in vitro synthesis, and coimmunoprecipitation from cell extracts shows that the site of interaction is between the terminal amino group of FANCA and the central part of BRCA1, located within amino acids 740–1083.[16][26]

However, as FANCA and BRCA1 undergo a constitutive interaction, this may not depend solely on detection of actual DNA damage. Instead BRCA1 protein may be more crucial in the detection of double stranded DNA breaks, or an intermediate in interstrand crosslink (ICL) repair, and rather serve to bring some of the many DNA repair proteins it interacts with to the site. One such protein would be FANCA, which in turn may serve as a docking site or anchor point at the site of ICL damage for the FA core complex.[26] Other FANC proteins, such as FANCC, FANCE and FANCG are then assembled in this nuclear complex in the presence of FANCA as required for the action of FANCD2. This mechanic is also supported by the protein-protein interactions between BRG1 and both BRCA1 and FANCA, that serve to modulate cell-cycle kinetics alongside this.[27] Alternatively, BRCA1 might localize FANCA to the site of DNA damage and then release it to initiate complex formation.[10][26] The complex would allow ubiquitination of FANCD2, a later functioning protein in the FA path, promoting ICL and DNA repair.

FANCA’s emerging putative and clearly integral function within activation the FA core complex also provides an explanation for its particularly high correlation with mutations causing Fanconi anaemia. Whilst many FANC protein mutations account for only 1% of the total observed cases,[6] they are also stabilized by FANCA within the complex. For example, FANCA stabilises FANCG within the core complex, and hence mutations in FANCG are compensated for as the complex can still catalyse FANCD2-ubiquitination further downstream. FANCA upregulation also increases expression of FANCG in cells, and the fact this transduction is not mutual – FANCG upregulation does not cause increased expression of FANCA – suggests that FANCA is not only the primary stabilizing protein in the core complex, but may act as a natural regulator in patients who would otherwise suffer from mutations in FANC genes other than FANCA or FANCD2.[28][29]

Participation in haematopoiesis

FANCA is hypothesised to play a crucial role in adult (definitive) haematopoiesis during embryonic development, and is thought to be expressed in all haematopoietic sites that contribute to the formation of haematopoietic stem cells and progenitor cells (HSPCs). Most patients with a mutation develop haematological abnormalities within the first decade of life,[7] and continue to decline until developing its most prevalent adverse effect, pancytopenia, potentially leading to death.[6] In particular many patients develop megaloblastic anaemia around the age of 7, with this macrocytosis being the first haematological marker.[7] Defective in vitro haematopoiesis has been recorded for over two decades resulting from mutated FANCA proteins, in particular developmental defects such as impaired granulomonocytopoiesis due to FANCA mutation.[30]

Studies using clonogenic myeloid progenitors (CFU-GM) have also shown that the frequency of CFU-GM in normal bone marrow increased and their proliferative capacity decreased exponentially with age, with a particularly marked proliferative impairment in Fanconi anaemia afflicted children compared to age-matched healthy controls.[31][32] As haematopoietic progenitor cell function begins at birth and continues throughout life, it is easily inferred that prolonged incapacitation of FANCA protein production results in total haematopoietic failure in patients.

Potential impact on erythroid development

The three distinct stages of mammalian erythroid development are primitive, foetal and adult definitive. Adult, or definitive erythrocytes are the most common blood cell type and characteristically most similar across mammalian species.[33] Primitive and foetal erythrocytes however, have markedly different characteristics. These include: they are larger in size (primitive even more so than foetal), circulate during early stages of development with a shorter lifespan, and, in particular, primitive cells are nucleated.[34]

As the reasons for these disparities are not well understood, FANCA may be a gene responsible for instigating these morphological differences when considering its variations in erythrocyte expression.[35] In primitive and foetal erythrocyte precursors, FANCA expression is low, and almost zero during reticulocyte formation. The marginal overall increase in the foetal stage is dwarfed by its sudden increase in expression solely during adult definitive proerythroblast formation. Here, the mean expression increases by 400% compared to foetal and primitive erythrocytes, and covers a huge margin of deviation.[35] As FANCA is heavily implicated in controlling cellular proliferation, and often results in patients developing megaloblastic anaemia around age 7,[6] a haematological disorder marked physically by proliferation-impaired, oversized erythrocytes, it is possible that the size and proliferative discrepancies between primitive, foetal and adult erythroid lineages may be explained by FANCA expression. As FANCA is also linked to cell-cycling and its progression from G2 phase, the stage impaired in megaloblastic anaemia, its expression in definitive proerythroblast development may be an upstream determinant of erythroid size.

Implications in cancer

FANCA mutations have also been implicated in increased risks of cancer and malignancies.[7] For example, patients with homozygous null-mutations in FANCA have a markedly increased susceptibility to acute myeloid leukaemia.[21] Furthermore, as FANC mutations in general affect DNA repair throughout the body and are predisposed to affect dynamic cell division particularly in bone marrow, it is unsurprising that patients are more likely to develop myelodysplastic syndromes (MDS) and acute myeloid leukaemia.[6]

Mouse knockout

Knockout mice have been generated for FANCA.[13] However, both single and double knockout murine models are healthy, viable, and do not readily show the phenotypic abnormalities typical of human Fanconi anaemia sufferers, such as haematological failure and increased susceptibility to cancers. Other markers such as infertility however still do arise.[7][36] This can be seen as evidence for a lack of functional redundancy in the FANCA gene-encoded proteins.[37] Murine models instead require induction of typical anaemic phenotypes by elevated dosing with MMC that does not affect wild-type animals, before they can be used experimentally as preclinical models for bone marrow failure and potential stem cell transplant or gene therapies.[6][37]

Both female and male mice homozygous for a FANCA mutation show hypogonadism and impaired fertility.[38] Homozygous mutant females exhibit premature reproductive senescence and an increased frequency of ovarian cysts.

In spermatocytes, the FANCA protein is ordinarily present at a high level during the pachytene stage of meiosis.[39] This is the stage when chromosomes are fully synapsed, and Holliday junctions are formed and then resolved into recombinants. FANCA mutant males exhibit an increased frequency of mispaired meiotic chromosomes, implying a role for FANCA in meiotic recombination. Also apoptosis is increased in the mutant germ cells. The Fanconi anemia DNA repair pathway appears to play a key role in meiotic recombination and the maintenance of reproductive germ cells.[39]

Loss of FANCA provokes neural progenitor apoptosis during forebrain development, likely related to defective DNA repair.[40] This effect persists in adulthood leading to depletion of the neural stem cell pool with aging. The Fanconi anemia phenotype can be interpreted as a premature aging of stem cells, DNA damages being the driving force of aging.[40] (Also see DNA damage theory of aging.)


FANCA has been shown to interact with:


  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000187741 - Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000032815 - Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ a b c "Entrez Gene: FANCA Fanconi anemia, complementation group A".
  6. ^ a b c d e f g h i Dokal I (2006). "Fanconi's anaemia and related bone marrow failure syndromes". Br. Med. Bull. 77–78: 37–53. doi:10.1093/bmb/ldl007. PMID 16968690.
  7. ^ a b c d e f g Tischkowitz MD, Hodgson SV (January 2003). "Fanconi anaemia". J. Med. Genet. 40 (1): 1–10. doi:10.1136/jmg.40.1.1. PMC 1735271. PMID 12525534.
  8. ^ "FANCA Gene protein-coding". Retrieved 24 October 2013.
  9. ^ "(FANCA_HUMAN)". Retrieved 24 October 2013.
  10. ^ a b D'Andrea AD, Grompe M (January 2003). "The Fanconi anaemia/BRCA pathway". Nat. Rev. Cancer. 3 (1): 23–34. doi:10.1038/nrc970. PMID 12509764.
  11. ^ Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, Grompe M, D'Andrea AD (February 2001). "Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway". Mol. Cell. 7 (2): 249–62. doi:10.1016/S1097-2765(01)00173-3. PMID 11239454.
  12. ^ a b Yuan F, Qian L, Zhao X, Liu JY, Song L, D'Urso G, Jain C, Zhang Y (February 2012). "Fanconi anemia complementation group A (FANCA) protein has intrinsic affinity for nucleic acids with preference for single-stranded forms". J. Biol. Chem. 287 (7): 4800–7. doi:10.1074/jbc.M111.315366. PMC 3281618. PMID 22194614.
  13. ^ a b c van de Vrugt HJ, Cheng NC, de Vries Y, Rooimans MA, de Groot J, Scheper RJ, Zhi Y, Hoatlin ME, Joenje H, Arwert F (April 2000). "Cloning and characterization of murine fanconi anemia group A gene: Fanca protein is expressed in lymphoid tissues, testis, and ovary". Mamm. Genome. 11 (4): 326–31. doi:10.1007/s003350010060. PMID 10754110.
  14. ^ Walsh CE, Yountz MR, Simpson DA (June 1999). "Intracellular localization of the Fanconi anemia complementation group A protein". Biochem. Biophys. Res. Commun. 259 (3): 594–9. doi:10.1006/bbrc.1999.0768. PMID 10364463.
  15. ^ Xie Y, de Winter JP, Waisfisz Q, Nieuwint AW, Scheper RJ, Arwert F, Hoatlin ME, Ossenkoppele GJ, Schuurhuis GJ, Joenje H (December 2000). "Aberrant Fanconi anaemia protein profiles in acute myeloid leukaemia cells". Br. J. Haematol. 111 (4): 1057–64. doi:10.1111/j.1365-2141.2000.02450.x. PMID 11167740.
  16. ^ a b c d Reuter TY, Medhurst AL, Waisfisz Q, Zhi Y, Herterich S, Hoehn H, Gross HJ, Joenje H, Hoatlin ME, Mathew CG, Huber PA (2003). "Yeast two-hybrid screens imply involvement of Fanconi anemia proteins in transcription regulation, cell signaling, oxidative metabolism, and cellular transport". Exp. Cell Res. 289 (2): 211–21. doi:10.1016/S0014-4827(03)00261-1. PMID 14499622.
  17. ^ The Fanconi Anaemia/Breast Cancer Consortium. (1996). "Positional cloning of the Fanconi anaemia group A gene". Nat. Genet. 14 (3): 324–8. doi:10.1038/ng1296-488b. PMID 8896564.
  18. ^ Wijker M; Morgan NV; Herterich S; van Berkel CG; Tipping AJ; Gross HJ; Gille JJ; Pals G; Savino M; Altay C; Mohan S; Dokal I; Cavenagh J; Marsh J; van Weel M; Ortega JJ; Schuler D; Samochatova E; Karwacki M; Bekassy AN; Abecasis M; Ebell W; Kwee ML; de Ravel T; CG Mathew (January 1999). "Heterogeneous spectrum of mutations in the Fanconi anaemia group A gene". Eur. J. Hum. Genet. 7 (1): 52–9. doi:10.1038/sj.ejhg.5200248. PMID 10094191.
  19. ^ Levran O, Erlich T, Magdalena N, Gregory JJ, Batish SD, Verlander PC, Auerbach AD (November 1997). "Sequence variation in the Fanconi anemia gene FAA". Proc. Natl. Acad. Sci. U.S.A. 94 (24): 13051–6. Bibcode:1997PNAS...9413051L. doi:10.1073/pnas.94.24.13051. PMC 24261. PMID 9371798.
  20. ^ Morgan NV, Tipping AJ, Joenje H, Mathew CG (November 1999). "High frequency of large intragenic deletions in the Fanconi anemia group A gene". Am. J. Hum. Genet. 65 (5): 1330–41. doi:10.1086/302627. PMC 1288285. PMID 10521298.
  21. ^ a b Adachi D, Oda T, Yagasaki H, Nakasato K, Taniguchi T, D'Andrea AD, Asano S, Yamashita T (December 2002). "Heterogeneous activation of the Fanconi anemia pathway by patient-derived FANCA mutants". Hum. Mol. Genet. 11 (25): 3125–34. CiteSeerX doi:10.1093/hmg/11.25.3125. PMID 12444097.
  22. ^ Tipping AJ, Pearson T, Morgan NV, Gibson RA, Kuyt LP, Havenga C, Gluckman E, Joenje H, de Ravel T, Jansen S, Mathew CG (May 2001). "Molecular and genealogical evidence for a founder effect in Fanconi anemia families of the Afrikaner population of South Africa". Proc. Natl. Acad. Sci. U.S.A. 98 (10): 5734–9. Bibcode:2001PNAS...98.5734T. doi:10.1073/pnas.091402398. PMC 33282. PMID 11344308.
  23. ^ a b c Medhurst AL, Huber PA, Waisfisz Q, de Winter JP, Mathew CG (2001). "Direct interactions of the five known Fanconi anaemia proteins suggest a common functional pathway". Hum. Mol. Genet. 10 (4): 423–9. doi:10.1093/hmg/10.4.423. PMID 11157805.
  24. ^ a b Pace P, Johnson M, Tan WM, Mosedale G, Sng C, Hoatlin M, de Winter J, Joenje H, Gergely F, Patel KJ (2002). "FANCE: the link between Fanconi anaemia complex assembly and activity". EMBO J. 21 (13): 3414–23. doi:10.1093/emboj/cdf355. PMC 125396. PMID 12093742.
  25. ^ a b Huber PA, Medhurst AL, Youssoufian H, Mathew CG (2000). "Investigation of Fanconi anemia protein interactions by yeast two-hybrid analysis". Biochem. Biophys. Res. Commun. 268 (1): 73–7. doi:10.1006/bbrc.1999.2055. PMID 10652215.
  26. ^ a b c d e Folias A, Matkovic M, Bruun D, Reid S, Hejna J, Grompe M, D'Andrea A, Moses R (2002). "BRCA1 interacts directly with the Fanconi anemia protein FANCA". Hum. Mol. Genet. 11 (21): 2591–7. doi:10.1093/hmg/11.21.2591. PMID 12354784.
  27. ^ a b Otsuki T, Furukawa Y, Ikeda K, Endo H, Yamashita T, Shinohara A, Iwamatsu A, Ozawa K, Liu JM (2001). "Fanconi anemia protein, FANCA, associates with BRG1, a component of the human SWI/SNF complex". Hum. Mol. Genet. 10 (23): 2651–60. doi:10.1093/hmg/10.23.2651. PMID 11726552.
  28. ^ Lensch, MW; et al. (2003). "Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia". Blood. 102 (1): 7–16. doi:10.1182/blood-2002-09-2781. PMID 12637330.
  29. ^ a b c Reuter T, Herterich S, Bernhard O, Hoehn H, Gross HJ (2000). "Strong FANCA/FANCG but weak FANCA/FANCC interaction in the yeast 2-hybrid system". Blood. 95 (2): 719–20. doi:10.1182/blood.V95.2.719. PMID 10627486.
  30. ^ Stark R, Thierry D, Richard P, Gluckman E (April 1993). "Long-term bone marrow culture in Fanconi's anaemia". Br. J. Haematol. 83 (4): 554–9. doi:10.1111/j.1365-2141.1993.tb04690.x. PMID 8518173.
  31. ^ Marley SB, Lewis JL, Davidson RJ, Roberts IA, Dokal I, Goldman JM, Gordon MY (July 1999). "Evidence for a continuous decline in haemopoietic cell function from birth: application to evaluating bone marrow failure in children". Br. J. Haematol. 106 (1): 162–6. doi:10.1046/j.1365-2141.1999.01477.x. PMID 10444180.
  32. ^ Verlinsky Y, Rechitsky S, Schoolcraft W, Strom C, Kuliev A (June 2001). "Preimplantation diagnosis for Fanconi anemia combined with HLA matching". JAMA. 285 (24): 3130–3. doi:10.1001/jama.285.24.3130. PMID 11427142.
  33. ^ Pierigè F, Serafini S, Rossi L, Magnani M (January 2008). "Cell-based drug delivery". Adv. Drug Deliv. Rev. 60 (2): 286–95. doi:10.1016/j.addr.2007.08.029. PMID 17997501.
  34. ^ Crowley J, Ways P, Jones JW (June 1965). "Human fetal erythrocyte and plasma lipids". J. Clin. Invest. 44 (6): 989–98. doi:10.1172/JCI105216. PMC 292579. PMID 14322033.
  35. ^ a b Kingsley PD, Greenfest-Allen E, Frame JM, Bushnell TP, Malik J, McGrath KE, Stoeckert CJ, Palis J (February 2013). "Ontogeny of erythroid gene expression". Blood. 121 (6): e5–e13. doi:10.1182/blood-2012-04-422394. PMC 3567347. PMID 23243273.
  36. ^ Liu JM, Kim S, Read EJ, Futaki M, Dokal I, Carter CS, Leitman SF, Pensiero M, Young NS, Walsh CE (September 1999). "Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC)". Hum. Gene Ther. 10 (14): 2337–46. doi:10.1089/10430349950016988. PMID 10515453.
  37. ^ a b Joenje H, Patel KJ (June 2001). "The emerging genetic and molecular basis of Fanconi anaemia". Nat. Rev. Genet. 2 (6): 446–57. doi:10.1038/35076590. PMID 11389461.
  38. ^ Cheng NC, van de Vrugt HJ, van der Valk MA, Oostra AB, Krimpenfort P, de Vries Y, Joenje H, Berns A, Arwert F (2000). "Mice with a targeted disruption of the Fanconi anemia homolog Fanca". Hum. Mol. Genet. 9 (12): 1805–11. doi:10.1093/hmg/9.12.1805. PMID 10915769.
  39. ^ a b Wong JC, Alon N, Mckerlie C, Huang JR, Meyn MS, Buchwald M (2003). "Targeted disruption of exons 1 to 6 of the Fanconi Anemia group A gene leads to growth retardation, strain-specific microphthalmia, meiotic defects and primordial germ cell hypoplasia". Hum. Mol. Genet. 12 (16): 2063–76. doi:10.1093/hmg/ddg219. PMID 12913077.
  40. ^ a b Sii-Felice K, Barroca V, Etienne O, Riou L, Hoffschir F, Fouchet P, Boussin FD, Mouthon MA (2008). "Role of Fanconi DNA repair pathway in neural stem cell homeostasis". Cell Cycle. 7 (13): 1911–5. doi:10.4161/cc.7.13.6235. PMID 18604174.
  41. ^ a b c d Otsuki T, Young DB, Sasaki DT, Pando MP, Li J, Manning A, Hoekstra M, Hoatlin ME, Mercurio F, Liu JM (2002). "Fanconi anemia protein complex is a novel target of the IKK signalsome". J. Cell. Biochem. 86 (4): 613–23. doi:10.1002/jcb.10270. PMID 12210728.
  42. ^ Sridharan D, Brown M, Lambert WC, McMahon LW, Lambert MW (2003). "Nonerythroid alphaII spectrin is required for recruitment of FANCA and XPF to nuclear foci induced by DNA interstrand cross-links". J. Cell Sci. 116 (Pt 5): 823–35. doi:10.1242/jcs.00294. PMID 12571280.
  43. ^ a b c d Meetei AR, de Winter JP, Medhurst AL, Wallisch M, Waisfisz Q, van de Vrugt HJ, Oostra AB, Yan Z, Ling C, Bishop CE, Hoatlin ME, Joenje H, Wang W (2003). "A novel ubiquitin ligase is deficient in Fanconi anemia". Nat. Genet. 35 (2): 165–70. doi:10.1038/ng1241. PMID 12973351.
  44. ^ a b c Taniguchi T, D'Andrea AD (2002). "The Fanconi anemia protein, FANCE, promotes the nuclear accumulation of FANCC". Blood. 100 (7): 2457–62. doi:10.1182/blood-2002-03-0860. PMID 12239156.
  45. ^ a b de Winter JP, van der Weel L, de Groot J, Stone S, Waisfisz Q, Arwert F, Scheper RJ, Kruyt FA, Hoatlin ME, Joenje H (2000). "The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG". Hum. Mol. Genet. 9 (18): 2665–74. doi:10.1093/hmg/9.18.2665. PMID 11063725.
  46. ^ Léveillé F, Blom E, Medhurst AL, Bier P, Laghmani el H, Johnson M, Rooimans MA, Sobeck A, Waisfisz Q, Arwert F, Patel KJ, Hoatlin ME, Joenje H, de Winter JP (2004). "The Fanconi anemia gene product FANCF is a flexible adaptor protein". J. Biol. Chem. 279 (38): 39421–30. doi:10.1074/jbc.M407034200. PMID 15262960.
  47. ^ a b Garcia-Higuera I, Kuang Y, Näf D, Wasik J, D'Andrea AD (1999). "Fanconi anemia proteins FANCA, FANCC, and FANCG/XRCC9 interact in a functional nuclear complex". Mol. Cell. Biol. 19 (7): 4866–73. doi:10.1128/mcb.19.7.4866. PMC 84285. PMID 10373536.
  48. ^ a b Thomashevski A, High AA, Drozd M, Shabanowitz J, Hunt DF, Grant PA, Kupfer GM (2004). "The Fanconi anemia core complex forms four complexes of different sizes in different subcellular compartments". J. Biol. Chem. 279 (25): 26201–9. doi:10.1074/jbc.M400091200. PMID 15082718.
  49. ^ Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, Li N, Berriz GF, Gibbons FD, Dreze M, Ayivi-Guedehoussou N, Klitgord N, Simon C, Boxem M, Milstein S, Rosenberg J, Goldberg DS, Zhang LV, Wong SL, Franklin G, Li S, Albala JS, Lim J, Fraughton C, Llamosas E, Cevik S, Bex C, Lamesch P, Sikorski RS, Vandenhaute J, Zoghbi HY, Smolyar A, Bosak S, Sequerra R, Doucette-Stamm L, Cusick ME, Hill DE, Roth FP, Vidal M (2005). "Towards a proteome-scale map of the human protein-protein interaction network". Nature. 437 (7062): 1173–8. Bibcode:2005Natur.437.1173R. doi:10.1038/nature04209. PMID 16189514.
  50. ^ Park SJ, Ciccone SL, Beck BD, Hwang B, Freie B, Clapp DW, Lee SH (2004). "Oxidative stress/damage induces multimerization and interaction of Fanconi anemia proteins". J. Biol. Chem. 279 (29): 30053–9. doi:10.1074/jbc.M403527200. PMID 15138265.
  51. ^ van de Vrugt HJ, Koomen M, Berns MA, de Vries Y, Rooimans MA, van der Weel L, Blom E, de Groot J, Schepers RJ, Stone S, Hoatlin ME, Cheng NC, Joenje H, Arwert F (2002). "Characterization, expression and complex formation of the murine Fanconi anaemia gene product Fancg". Genes Cells. 7 (3): 333–42. doi:10.1046/j.1365-2443.2002.00518.x. PMID 11918676.
  52. ^ Yagasaki H, Adachi D, Oda T, Garcia-Higuera I, Tetteh N, D'Andrea AD, Futaki M, Asano S, Yamashita T (2001). "A cytoplasmic serine protein kinase binds and may regulate the Fanconi anemia protein FANCA". Blood. 98 (13): 3650–7. doi:10.1182/blood.V98.13.3650. PMID 11739169.
  53. ^ Gordon SM, Buchwald M (2003). "Fanconi anemia protein complex: mapping protein interactions in the yeast 2- and 3-hybrid systems". Blood. 102 (1): 136–41. doi:10.1182/blood-2002-11-3517. PMID 12649160.
  54. ^ Kruyt FA, Abou-Zahr F, Mok H, Youssoufian H (1999). "Resistance to mitomycin C requires direct interaction between the Fanconi anemia proteins FANCA and FANCG in the nucleus through an arginine-rich domain". J. Biol. Chem. 274 (48): 34212–8. doi:10.1074/jbc.274.48.34212. PMID 10567393.
  55. ^ Blom E, van de Vrugt HJ, de Vries Y, de Winter JP, Arwert F, Joenje H (2004). "Multiple TPR motifs characterize the Fanconi anemia FANCG protein". DNA Repair (Amst.). 3 (1): 77–84. doi:10.1016/j.dnarep.2003.09.007. PMID 14697762.
  56. ^ Kuang Y, Garcia-Higuera I, Moran A, Mondoux M, Digweed M, D'Andrea AD (2000). "Carboxy terminal region of the Fanconi anemia protein, FANCG/XRCC9, is required for functional activity". Blood. 96 (5): 1625–32. doi:10.1182/blood.V96.5.1625. PMID 10961856.
  57. ^ Waisfisz Q, de Winter JP, Kruyt FA, de Groot J, van der Weel L, Dijkmans LM, Zhi Y, Arwert F, Scheper RJ, Youssoufian H, Hoatlin ME, Joenje H (1999). "A physical complex of the Fanconi anemia proteins FANCG/XRCC9 and FANCA". Proc. Natl. Acad. Sci. U.S.A. 96 (18): 10320–5. Bibcode:1999PNAS...9610320W. doi:10.1073/pnas.96.18.10320. PMC 17886. PMID 10468606.
  58. ^ Garcia-Higuera I, Kuang Y, Denham J, D'Andrea AD (2000). "The fanconi anemia proteins FANCA and FANCG stabilize each other and promote the nuclear accumulation of the Fanconi anemia complex". Blood. 96 (9): 3224–30. doi:10.1182/blood.V96.9.3224. PMID 11050007.
  59. ^ a b McMahon LW, Walsh CE, Lambert MW (1999). "Human alpha spectrin II and the Fanconi anemia proteins FANCA and FANCC interact to form a nuclear complex". J. Biol. Chem. 274 (46): 32904–8. doi:10.1074/jbc.274.46.32904. PMID 10551855.
  60. ^ Otsuki T, Kajigaya S, Ozawa K, Liu JM (1999). "SNX5, a new member of the sorting nexin family, binds to the Fanconi anemia complementation group A protein". Biochem. Biophys. Res. Commun. 265 (3): 630–5. doi:10.1006/bbrc.1999.1731. PMID 10600472.
  61. ^ McMahon LW, Sangerman J, Goodman SR, Kumaresan K, Lambert MW (2001). "Human alpha spectrin II and the FANCA, FANCC, and FANCG proteins bind to DNA containing psoralen interstrand cross-links". Biochemistry. 40 (24): 7025–34. doi:10.1021/bi002917g. PMID 11401546.
  62. ^ Tremblay CS.; et al. (2008). "HES1 is a novel interactor of the Fanconi anemia core complex". Blood. 112 (5): 2062–2070. doi:10.1182/blood-2008-04-152710. PMC 5154739. PMID 18550849.

This page is based on a Wikipedia article. The text is available under the Creative Commons Attribution/Share-Alike License.

This tab holds the annotation information that is stored in the Pfam database. As we move to using Wikipedia as our main source of annotation, the contents of this tab will be gradually replaced by the Wikipedia tab.

Fanconi anaemia group A protein Provide feedback

No Pfam abstract.

This tab holds annotation information from the InterPro database.

InterPro entry IPR003516

Fanconi anemia (FA) is a human disorder characterized by cancer susceptibility and cellular sensitivity to DNA crosslinks and other damages. The FA complex repairs the interstrand cross-linking (ICL) lesions and coordinates activities of the downstream DNA repair pathway including nucleotide excision repair, translesion synthesis, and homologous recombination. It is required for the monoubiquitylation of FANCD2 and FANCI heterodimer. The FA core complex consists of FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCM, FANCT (UBET2), FAAP100 and FAAP24 [PUBMED:29017571, PUBMED:20347428].

This entry represents FANCA [PUBMED:29017571].

Gene Ontology

The mapping between Pfam and Gene Ontology is provided by InterPro. If you use this data please cite InterPro.

Domain organisation

Below is a listing of the unique domain organisations or architectures in which this domain is found. More...

Loading domain graphics...


We store a range of different sequence alignments for families. As well as the seed alignment from which the family is built, we provide the full alignment, generated by searching the sequence database (reference proteomes) using the family HMM. We also generate alignments using four representative proteomes (RP) sets, the UniProtKB sequence database, the NCBI sequence database, and our metagenomics sequence database. More...

View options

We make a range of alignments for each Pfam-A family. You can see a description of each above. You can view these alignments in various ways but please note that some types of alignment are never generated while others may not be available for all families, most commonly because the alignments are too large to handle.

Representative proteomes UniProt
Jalview View  View  View  View  View  View  View  View   
HTML View  View               
PP/heatmap 1 View               

1Cannot generate PP/Heatmap alignments for seeds; no PP data available

Key: ✓ available, x not generated, not available.

Format an alignment

Representative proteomes UniProt

Download options

We make all of our alignments available in Stockholm format. You can download them here as raw, plain text files or as gzip-compressed files.

Representative proteomes UniProt
Raw Stockholm Download   Download   Download   Download   Download   Download   Download   Download    
Gzipped Download   Download   Download   Download   Download   Download   Download   Download    

You can also download a FASTA format file containing the full-length sequences for all sequences in the full alignment.

HMM logo

HMM logos is one way of visualising profile HMMs. Logos provide a quick overview of the properties of an HMM in a graphical form. You can see a more detailed description of HMM logos and find out how you can interpret them here. More...


This page displays the phylogenetic tree for this family's seed alignment. We use FastTree to calculate neighbour join trees with a local bootstrap based on 100 resamples (shown next to the tree nodes). FastTree calculates approximately-maximum-likelihood phylogenetic trees from our seed alignment.

Note: You can also download the data file for the tree.

Curation and family details

This section shows the detailed information about the Pfam family. You can see the definitions of many of the terms in this section in the glossary and a fuller explanation of the scoring system that we use in the scores section of the help pages.

Curation View help on the curation process

Seed source: PRINTS
Previous IDs: Fanconia;
Type: Family
Sequence Ontology: SO:0100021
Author: Griffiths-Jones SR
Number in seed: 14
Number in full: 154
Average length of the domain: 59.60 aa
Average identity of full alignment: 47 %
Average coverage of the sequence by the domain: 4.62 %

HMM information View help on HMM parameters

HMM build commands:
build method: hmmbuild -o /dev/null HMM SEED
search method: hmmsearch -Z 47079205 -E 1000 --cpu 4 HMM pfamseq
Model details:
Parameter Sequence Domain
Gathering cut-off 20.9 20.9
Trusted cut-off 21.0 21.0
Noise cut-off 20.8 20.8
Model length: 63
Family (HMM) version: 15
Download: download the raw HMM for this family

Species distribution

Sunburst controls


Weight segments by...

Change the size of the sunburst


Colour assignments

Archea Archea Eukaryota Eukaryota
Bacteria Bacteria Other sequences Other sequences
Viruses Viruses Unclassified Unclassified
Viroids Viroids Unclassified sequence Unclassified sequence


Align selected sequences to HMM

Generate a FASTA-format file

Clear selection

This visualisation provides a simple graphical representation of the distribution of this family across species. You can find the original interactive tree in the adjacent tab. More...

Loading sunburst data...

Tree controls


The tree shows the occurrence of this domain across different species. More...


Please note: for large trees this can take some time. While the tree is loading, you can safely switch away from this tab but if you browse away from the family page entirely, the tree will not be loaded.